评估NSABP B-18、B-27、B-40和B-41试验中区域淋巴结照射的分配及其与肿瘤学结局的关联
利用NSABP B-18、B-27、B-40和B-41四项新辅助化疗试验数据,分析区域淋巴结照射(RNI)的分配因素及其与肿瘤学结局的关联。多因素分析显示肿瘤大小、ypN状态和肿瘤亚型与RNI显著相关,西班牙裔患者接受RNI的可能性较低。ypN+HER2+患者接受RNI总生存改善,B-40中ypN+HR+患者局部区域复发改善,但RNI与全队列的OS、无病生存、远处复发或LRR无显著关联。
要点
- ypN+HER2+疾病患者接受RNI与总生存改善相关。
- B-40中ypN+HR+疾病患者接受RNI与局部区域复发改善相关。
- 全队列中RNI与OS、无病生存、远处复发或LRR无显著关联。
核心结论
- RNI与ypN+HER2+和ypN+HR+疾病患者的临床获益相关。
- RNI与整个队列的临床获益结局无显著关联。
- 需要前瞻性3期临床试验来确立新辅助治疗后应接受RNI的患者指南,并需要采取行动消除西班牙裔女性在诊疗中显示的差异。
研究设计与样本
- 利用NSABP B-18、B-27、B-40和B-41临床试验的数据进行分析。
- B-40和B-41允许医生自行决定是否进行RNI。
- B-18、B-27、B-40和B-41的中位随访时间分别为13.7年、9.7年、4.5年和5.1年,纳入分析的患者数分别为742例、2254例、1154例和504例。
主要发现
- 多因素分析中,与RNI显著相关的因素包括肿瘤大小、ypN状态和肿瘤亚型;西班牙裔患者接受RNI的可能性较低。
- ypN+HER2+疾病患者接受RNI与总生存改善相关。
- B-40中ypN+HR+疾病患者接受RNI与局部区域复发改善相关。
- 在B-40和B-41研究人群的多因素分析中,RNI与总生存、无病生存、远处复发或局部区域复发的显著改善无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要前瞻性3期临床试验来确立新辅助治疗后应接受RNI的患者指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is a lack of level I evidence to guide radiation therapy recommendations for patients receiving neoadjuvant chemotherapy for breast cancer. We used 4 neoadjuvant chemotherapy trials to determine which patients benefit from regional nodal irradiation (RNI). METHODS AND MATERIALS: We obtained data from the NSABP (National Surgical Adjuvant Breast and Bowel Project) B-18, B-27, B-40, and B-41 clinical trials. B-40 and B-41 allowed RNI at physician's discretion. We evaluated locoregional recurrence (LRR), distant recurrence, disease-free survival, and overall survival (OS). Kaplan-Meier, Peto-Peto, χ2, Fisher exact, and Wilcoxon rank-sum tests were used for survival estimates and comparison. RESULTS: Median follow-up for B-18, B-27, B-40, and B-41 was 13.7, 9.7, 4.5, and 5.1 years, respectively, including 742, 2254, 1154, and 504 patients for analysis. On multivariable analysis, factors significantly associated with RNI included tumor size, ypN status, and tumor subtype; Hispanic patients were less likely to receive RNI. Patients with ypN+HER2+ disease who received RNI had improved OS. B-40 patients with ypN+HR+ disease had improved LRR. On multivariable analysis for the B-40 and B-41 study population, RNI was not associated with significantly improved OS, disease-free survival, distant recurrence, or LRR. CONCLUSIONS: RNI was associated with a clinical benefit for patients with ypN+HER2+ and ypN+HR+ disease. RNI was not significantly associated with a clinically beneficial outcome for the entire cohort. Prospective phase 3 clinical trials are needed to establish guidelines for patients who should receive RNI after neoadjuvant treatment, and action is necessary to eliminate the disparity in care delivery shown for Hispanic women.
引用
- Mailhot Vega RB, Wang S, Brooks ED, et al. Evaluating Regional Nodal Irradiation Allocation and Association with Oncologic Outcomes in NSABP B-18, B-27, B-40, and B-41. Int J Radiat Oncol Biol Phys. 2022. PMID: 35418342. doi:10.1016/j.ijrobp.2022.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。